Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. (September 2017)

• Record Type: Journal Article
• Authors: Mukherjee, Chandrama; Sweet, Kevin M; Luzum, Jasmine A; Abdel-Rasoul, Mahmoud; Christman, Michael F; Kitzmiller, Joseph P
• Is Part Of: Personalized medicine. Volume 14:Number 5(2017)
• Page Start: 383
• Page End: 388
• Publication Date: 2017-09
• Subjects: actionable test results -- cardiovascular drugs -- clopidogrel -- patient perspectives -- personalized medicine -- pharmacogenetics -- pharmacogenomics -- precision medicine -- simvastatin -- warfarin; Pharmacogenomics -- Periodicals; Pharmacogenetics -- Periodicals; 615.19
• DOI: 10.2217/pme-2017-0022
• Languages: English
• ISSNs: 1741-0541

Abstract

Aim: This study aimed to examine pharmacogenomic test results and patient perspectives at an academic cardiovascular medicine clinic.Patients & methods: Test results for three common cardiovascular drug–gene tests (warfarin- CYP2C9-VKORC1, clopidogrel- CYP2C19 and simvastatin- SLCO1B1 ) of 208 patients in the Ohio State University-Coriell Personalized Medicine Collaborative were examined to determine the incidence of potentially actionable test results. A post-hoc, anonymous, patient survey was also conducted.Results: Potentially actionable test results for at least one of the three drug–gene tests were determined in 170 (82%) patients. Survey responses (n = 134) suggested that patients generally considered their test results to be important (median of 7.5 on a 10-point scale of importance) and were interested (median of 7.3 on a 10-point scale of interest) in a Clinical Pharmacogenomic Service.Conclusion: Attitudes toward pharmacogenomic testing were generally favorable, and potentially actionable test results were not uncommon in this cardiovascular medicine cohort.